Key terms

About IMNM

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest IMNM news

Yesterday 6:14am ET Immunome initiated with a Buy at Guggenheim by TipRanks Apr 08 3:50am ET Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM) by TipRanks Apr 05 8:16am ET Immunome to presents preclinical data for IM-3050 at AACR by TipRanks Apr 03 4:42pm ET Immunome files to sell 2.23M shares of common stock for holders by TipRanks Apr 03 4:38pm ET Immunome files to sell 2.18M shares of common stock for holders by TipRanks Apr 01 7:59am ET Immunome price target raised to $33 from $27 at Wedbush by TipRanks Apr 01 7:55am ET Immunome (IMNM) Receives a Buy from Wedbush by TipRanks Mar 29 3:20am ET Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM) by TipRanks Mar 28 5:35pm ET TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM) by TipRanks Mar 26 8:22am ET Immunome’s Strategic Acquisition to Revolutionize Cancer Treatment by TipRanks Mar 04 7:06am ET Shattuck Labs appoints Siegall, Sasser to board of directors by TipRanks Feb 22 12:18am ET Leerink Partners Sticks to Their Buy Rating for Immunome (IMNM) by TipRanks Feb 14 4:24pm ET Immunome Launches $200 Million Public Offering by TipRanks Feb 14 5:57am ET Immunome 10M share Spot Secondary priced at $20.00 by TipRanks Feb 13 4:45pm ET Immunome $200M Spot Secondary; price range $20.00-$21.00 by TipRanks Feb 13 4:45pm ET Immunome $200M Spot Secondary; price range $20.00-$21.00 by TipRanks Feb 13 4:24pm ET Immunome Updates Business Overview and Risks in SEC Filings by TipRanks Feb 13 4:07pm ET Immunome announces $200M common stock offering by TipRanks Feb 13 4:06pm ET Immunome files automatic mixed securities shelf by TipRanks Feb 09 11:12am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Feb 09 12:45am ET Immunome Upgraded to Buy on Strategic Acquisition and AL102’s Market Potential by TipRanks Feb 07 4:12am ET Immunome Unveils Purchase Agreement, Cautions on Projections by TipRanks Feb 07 4:12am ET Immunome Issues Private Equity Shares to Ayala by TipRanks Feb 07 4:12am ET Immunome Strikes Deal to Acquire Ayala’s Drug Programs by TipRanks Feb 06 8:21am ET Immunome to acquire AL102 from Ayala for $20M in cash, $30M in stock by TipRanks Feb 06 8:06am ET Immunome acquires AL102 a and AL101 from Ayala for $50M at closing by TipRanks Jan 23 7:44am ET Immunome price target raised to $19 from $12 at Wedbush by TipRanks

No recent press releases are available for IMNM

IMNM Financials

1-year income & revenue

Key terms

IMNM Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

IMNM Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching
Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments